Skip to main content

Table 2 Histological and genetic characteristics of the patients treated with a pemetrexed-containing therapy

From: Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

  Total (n = 314) Good responders (n = 92) Poor responders (n = 222) P-value
Histology     0.810
 Adenocarcinoma 285 (90.8) 83 (90.2) 202 (91.0)  
 Large cell carcinoma 5 (1.6) 2 (2.2) 3 (1.4)  
 NSCLC-NOS 24 (7.6) 7 (7.6) 17 (7.7)  
Subtype (n = 57)* 57 24 33 0.368
 Mucinous 22 (38.6) 10 (41.7) 12 (36.4)  
 Acinar 13 (22.8) 7 (29.2) 6 (18.2)  
 Papillary 13 (22.8) 4 (16.7) 9 (27.3)  
 Signet-ring 5 (8.8) 3 (12.5) 2 (6.1)  
 Solid 4 (7.0) 0 4 (12.1)  
Differentiation (n = 220) 220 63 157 0.001
 Well-differentiated 18 (8.2) 12 (19.0) 6 (3.8)  
 Moderately-differentiated 115 (52.3) 29 (46.0) 86 (54.8)  
 Poorly-differentiated 87 (39.5) 22 (34.9) 65 (41.4)  
TTF-1 expression (n = 151) 125 (82.8) 35 (94.6) 90 (78.9) 0.028
Gene mutation (n = 239) 239 72 167  
 EGFR mutation 89 (37.2) 12 (16.7) 77 (46.1) <0.001
 ALK translocation 23 (9.6) 16 (22.2) 7 (4.2) <0.001
 KRAS mutation 5 (2.1) 0 5 (3.0) 0.326
 Wild-type for EGFR/ALK/KRAS 122 (51.0) 44 (61.1) 78 (46.7) 0.041
  1. Data are shown as n (%) per each group, unless otherwise noted
  2. *The subtype was not subclassified according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung adenocarcinoma revised at 2011, for study subjects were recruited from 2006
  3. NSCLC-NOS Non-small-cell lung cancer-not otherwise specified; TTF-1 thyroid transcription factor-1; EGFR epidermal growth factor receptor; ALK anaplastic lymphoma kinase; KRAS Kirsten rat sarcoma viral oncogene homolog